Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029137 | 1.00 | CPB1 (0.43) | CPB1SMN1; SMN2TACR1TLR4ALDH1A1 | |
| SCHEMBL5030515 | 0.84 | CPB1 (0.50) | CPB1SMN1; SMN2TACR1TLR4ALDH1A1 | |
| SCHEMBL5030509 | 0.84 | CPB1 (0.50) | CPB1SMN1; SMN2TACR1TLR4ALDH1A1 | |
| SCHEMBL31650770 | 0.81 | CPB1 (0.51) | CPB1SMN1; SMN2TACR1TLR4ALDH1A1 | |
| SCHEMBL5029500 | 0.80 | CPB1 (0.46) | CPB1SMN1; SMN2TACR1ALDH1A1GAA | |
| SCHEMBL5029501 | 0.80 | CPB1 (0.46) | CPB1SMN1; SMN2TACR1ALDH1A1GAA | |
| SCHEMBL5029146 | 0.79 | CPB1 (0.45) | CPB1SMN1; SMN2TACR1ALDH1A1GAA | |
| SCHEMBL5031822 | 0.79 | PSMB5 (0.33) | SMN1; SMN2LMNA | |
| SCHEMBL17506913 | 0.77 | ALDH1A1 (0.56) | CPB1SMN1; SMN2TLR4ALDH1A1GAA | |
| SCHEMBL5030265 | 0.76 | CCR2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CPB1 764/4885SMN1; SMN2 2931/4885TACR1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.